Priovant pushes ex-Pfizer asset across FDA finish line in rare skin and muscle disease

Though not without a bump along the way, Roivant-backed Priovant Therapeutics has pushed its dual TYK2/JAK1 inhibitor across the FDA finish line, securing its first approval in a rare skin disease.